Poster presented at ECCMID 2023
Raphaël Saporta 1, Elisabet I. Nielsen 1, Valérie Nicolas-Métral 2, David R. Cameron 2,
Annick Menetrey 2, Lena E. Friberg 1
1 Department of Pharmacy, Uppsala University, Sweden
2 Debiopharm International SA, Lausanne, Switzerland
Background
Afabicin is a novel class antibiotic targeting the Fabl enzyme in staphylococci, in development for:
➢ Bone and joint infections due to staphylococci (currently in Phase II clinical trials)
➢ Staphylococcal acute bacterial skin and skin structure infections (Phase II completed)
• Static in vitro time-kill experiments were performed for various Staphylococcus aureus strains, to evaluate
the antimicrobial activity of the active moiety of afabicin, afabicin desphosphono (Debio 1452).
• Aim: Build a model characterizing afabicin desphosphono pharmacokinetics-pharmacodynamics (PK/PD)
based on the time-kill data to support further development of afabicin.